JP2010509331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509331A5 JP2010509331A5 JP2009536282A JP2009536282A JP2010509331A5 JP 2010509331 A5 JP2010509331 A5 JP 2010509331A5 JP 2009536282 A JP2009536282 A JP 2009536282A JP 2009536282 A JP2009536282 A JP 2009536282A JP 2010509331 A5 JP2010509331 A5 JP 2010509331A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- effective amount
- taxane
- vegf antibody
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940123237 Taxane Drugs 0.000 claims description 47
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 45
- 239000002105 nanoparticle Substances 0.000 claims description 34
- 206010027476 Metastases Diseases 0.000 claims description 22
- 230000009401 metastasis Effects 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 102000014914 Carrier Proteins Human genes 0.000 claims description 13
- 108010078791 Carrier Proteins Proteins 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 43
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/594,417 US20070166388A1 (en) | 2005-02-18 | 2006-11-06 | Combinations and modes of administration of therapeutic agents and combination therapy |
| US11/594,417 | 2006-11-06 | ||
| PCT/US2007/023446 WO2008057562A1 (en) | 2006-11-06 | 2007-11-06 | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013230872A Division JP2014043454A (ja) | 2006-11-06 | 2013-11-07 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509331A JP2010509331A (ja) | 2010-03-25 |
| JP2010509331A5 true JP2010509331A5 (https=) | 2011-12-15 |
| JP5931323B2 JP5931323B2 (ja) | 2016-06-08 |
Family
ID=39111840
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009536282A Active JP5931323B2 (ja) | 2006-11-06 | 2007-11-06 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
| JP2013230872A Withdrawn JP2014043454A (ja) | 2006-11-06 | 2013-11-07 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
| JP2015208557A Pending JP2016014073A (ja) | 2006-11-06 | 2015-10-23 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013230872A Withdrawn JP2014043454A (ja) | 2006-11-06 | 2013-11-07 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
| JP2015208557A Pending JP2016014073A (ja) | 2006-11-06 | 2015-10-23 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20070166388A1 (https=) |
| EP (3) | EP3108885A1 (https=) |
| JP (3) | JP5931323B2 (https=) |
| KR (4) | KR20150065957A (https=) |
| CN (2) | CN101573108A (https=) |
| AU (1) | AU2007317859B2 (https=) |
| BR (1) | BRPI0718528A2 (https=) |
| CA (1) | CA2668607A1 (https=) |
| CY (2) | CY1115271T1 (https=) |
| DK (2) | DK2097078T3 (https=) |
| ES (2) | ES2576289T3 (https=) |
| HU (1) | HUE028472T2 (https=) |
| IL (2) | IL198576A (https=) |
| MX (1) | MX2009004803A (https=) |
| NO (1) | NO343908B1 (https=) |
| NZ (1) | NZ576856A (https=) |
| PL (2) | PL2481405T3 (https=) |
| PT (2) | PT2481405E (https=) |
| RU (2) | RU2009121568A (https=) |
| SI (2) | SI2481405T1 (https=) |
| WO (1) | WO2008057562A1 (https=) |
| ZA (1) | ZA200903132B (https=) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US20070117862A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| PT1023050E (pt) * | 1997-06-27 | 2013-12-04 | Abraxis Bioscience Llc | Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização |
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| CA2509365C (en) * | 2002-12-09 | 2012-08-07 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| KR20070114753A (ko) * | 2005-02-18 | 2007-12-04 | 아브락시스 바이오사이언스 인크. | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| LT3311805T (lt) * | 2005-08-31 | 2020-04-27 | Abraxis Bioscience, Llc | Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus |
| EP3527202A1 (en) * | 2005-08-31 | 2019-08-21 | Abraxis BioScience, LLC | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| US8440625B2 (en) * | 2006-06-26 | 2013-05-14 | University Of British Columbia | Secreted protein acidic and rich in cysteine (SPARC) as chemotherapeutic sensitizers |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| JP2010508277A (ja) * | 2006-11-01 | 2010-03-18 | ジョージ メイソン インテレクチュアル プロパティーズ，インコーポレイテッド オブ フェアファックス，バージニア | 癌を検出および抑制するための方法 |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| EP2131821B1 (en) * | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| JP5579057B2 (ja) * | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス， エルエルシー | 再発性癌の処置のための方法および組成物 |
| WO2009002425A2 (en) * | 2007-06-22 | 2008-12-31 | Scidose Llc | Solubilized formulation of docetaxel without tween 80 |
| ITMI20080284A1 (it) * | 2008-02-22 | 2009-08-23 | Indena Spa | Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono |
| MX2010011165A (es) * | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
| EP2310006A4 (en) | 2008-07-03 | 2012-04-25 | Mayo Foundation | CANCER TREATMENT |
| EP2153821A1 (en) * | 2008-08-06 | 2010-02-17 | BioAlliance Pharma | Oral formulations of camptothecin derivatives |
| PL2387395T3 (pl) * | 2009-01-16 | 2015-03-31 | Rigel Pharmaceuticals Inc | Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym |
| WO2010105172A1 (en) | 2009-03-13 | 2010-09-16 | Abraxis Bioscience, Llc | Combination therapy with thiocolchicine derivatives |
| PT2419732T (pt) | 2009-04-15 | 2019-12-24 | Abraxis Bioscience Llc | Composições e métodos de nanopartículas isentas de priões |
| EP2451459B1 (en) * | 2009-07-07 | 2017-11-22 | Normoxys, Inc. | Method of reducing multi-drug resistance using inositol tripyrophosphate |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
| US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
| US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
| TWI619509B (zh) * | 2010-02-23 | 2018-04-01 | 建南德克公司 | 治療先前未經治療之ⅲ期或ⅳ期卵巢癌、輸卵管癌或原發性腹膜癌之卡鉑、太平洋紫杉醇與抗-vegf抗體之組合 |
| NZ602382A (en) * | 2010-03-26 | 2014-11-28 | Abraxis Bioscience Llc | Methods of treatment of hepatocellular carcinoma |
| EP3141245A1 (en) * | 2010-03-29 | 2017-03-15 | Abraxis BioScience, LLC | Methods of treating cancer |
| MX2012011155A (es) * | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
| MX347225B (es) | 2010-06-04 | 2017-04-19 | Abraxis Bioscience Llc * | Metodos de tratamiento contra el cancer pancreatico. |
| JP6031437B2 (ja) | 2010-06-07 | 2016-11-24 | アブラクシス バイオサイエンス， エルエルシー | 増殖性疾患を処置するための組み合わせ療法 |
| US20120121510A1 (en) * | 2010-11-11 | 2012-05-17 | Brem Rachel F | Localized therapy following breast cancer surgery |
| US20130323265A1 (en) * | 2010-11-15 | 2013-12-05 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with dll4 antagonists |
| AU2012253571A1 (en) | 2011-05-09 | 2014-01-09 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| TW201700103A (zh) | 2011-11-01 | 2017-01-01 | 西建公司 | 利用胞嘧啶核苷類似物之口服配方治療癌症的方法 |
| WO2013085902A1 (en) | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| DK2825558T3 (da) | 2012-03-13 | 2019-07-22 | Hoffmann La Roche | Kombinationsterapi til behandling af ovariecancer |
| US10413606B2 (en) | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) * | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| KR102148551B1 (ko) * | 2013-02-11 | 2020-08-26 | 아브락시스 바이오사이언스, 엘엘씨 | 흑색종을 치료하는 방법 |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| RU2015143490A (ru) | 2013-03-14 | 2017-04-26 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
| US10842969B2 (en) | 2013-10-25 | 2020-11-24 | Mercator Medsystems, Inc. | Systems and methods of treating malacia by local delivery of hydrogel to augment tissue |
| WO2015134543A1 (en) * | 2014-03-05 | 2015-09-11 | Sorrento Therapeutics, Inc. | Pharmacokinetically equivalent nanoparticle compositions |
| EP2924022A1 (en) * | 2014-03-27 | 2015-09-30 | INDENA S.p.A. | Amorphous form of a thiocolchicine derivative |
| EP3154586B1 (en) | 2014-06-13 | 2020-05-27 | Mayo Foundation for Medical Education and Research | Treating lymphomas |
| KR20170020371A (ko) | 2014-06-16 | 2017-02-22 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 골수종의 치료 |
| WO2015195634A1 (en) | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| WO2015018380A2 (en) * | 2014-07-03 | 2015-02-12 | Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. | Therapeutic nanoparticles and the preparation methods thereof |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| CR20170031A (es) * | 2014-10-06 | 2017-05-22 | Mayo Found For Medical Educaction And Res | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| ES3009356T3 (en) | 2015-06-29 | 2025-03-26 | Abraxis Bioscience Llc | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| WO2017176265A1 (en) * | 2016-04-06 | 2017-10-12 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| JP6921802B2 (ja) * | 2015-08-18 | 2021-08-18 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | キャリア結合剤組成物およびそれを作製および使用する方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| CN105288639A (zh) * | 2015-11-23 | 2016-02-03 | 中国药科大学 | 一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用 |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| WO2017139698A1 (en) * | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| EP3432926A4 (en) * | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| CN109922836A (zh) * | 2016-08-05 | 2019-06-21 | 梅奥医学教育和研究基金会 | 用于癌症治疗的经修饰抗体-白蛋白纳米颗粒复合物 |
| TWI771315B (zh) * | 2016-08-26 | 2022-07-21 | 奧野哲治 | 微小奈米化藥劑及其利用 |
| JP2019526579A (ja) | 2016-09-01 | 2019-09-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | Ｔ細胞癌を標的とする為の方法及び組成物 |
| WO2018045239A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Carrier-pd-l1 binding agent compositions for treating cancers |
| RU2021128415A (ru) | 2016-09-06 | 2021-11-08 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения |
| EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| KR20230011473A (ko) | 2016-09-06 | 2023-01-20 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | Ｐｄ－ｌ１ 발현 암의 치료 방법 |
| CN106310291A (zh) * | 2016-09-14 | 2017-01-11 | 东南大学 | 主动靶向抗肿瘤纳米药物及其制备方法和应用 |
| AU2017347853B2 (en) | 2016-10-27 | 2022-02-17 | Celgene Quanticel Research, Inc. | Bromodomain and extra-terminal protein inhibitor combination therapy |
| CA3042238C (en) * | 2016-10-28 | 2021-08-10 | Nant Holdings Ip, Llc | Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death |
| EP3706750A1 (en) | 2017-11-06 | 2020-09-16 | RAPT Therapeutics, Inc. | Chemokine receptor modulators for treatment of epstein barr virus positive cancer |
| WO2019104042A1 (en) * | 2017-11-21 | 2019-05-31 | University Of Iowa Research Foundation | Synthetically lethal nanoparticles for treatment of cancers |
| EP3727368A4 (en) * | 2017-12-19 | 2021-10-20 | Abraxis BioScience, LLC | METHOD OF TREATMENT IN COLON CANCER WITH NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY |
| AU2019212622B2 (en) | 2018-01-26 | 2024-05-23 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| BR112022007710A2 (pt) | 2019-10-28 | 2022-07-12 | Abraxis Bioscience Llc | Composições farmacêuticas de albumina e rapamicina |
| BR112022010113A2 (pt) | 2019-11-25 | 2022-09-06 | Univ California | Inibidores de vegf de longa ação para neovascularização intraocular |
| KR102263606B1 (ko) | 2020-02-11 | 2021-06-10 | 충북대학교 산학협력단 | 파클리탁셀과 알피늄이소플라본을 함유한 나노 마이셀, 이의 제조방법 및 이의 용도 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5470571A (en) | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
| IL98528A0 (en) | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
| CA2082160C (en) | 1991-03-06 | 2003-05-06 | Mary M. Bendig | Humanised and chimeric monoclonal antibodies |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| EP0739203A4 (en) | 1994-01-14 | 2000-12-20 | Cell Therapeutics Inc | METHOD OF TREATING CELL PROLIFERATION CONDITIONS IN RESPONSE TO PDGF, EGF, FGF AND VEGF |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| WO1999053935A1 (en) | 1998-04-16 | 1999-10-28 | Ida Development A/S | Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga |
| EP1171117A4 (en) | 1999-04-22 | 2002-08-07 | American Bioscience Inc | LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS |
| ITMI20001107A1 (it) * | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| US20040143004A1 (en) | 2002-02-26 | 2004-07-22 | Joseph Fargnoli | Metronomic dosing of taxanes |
| CA2509365C (en) | 2002-12-09 | 2012-08-07 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
| UA101945C2 (uk) * | 2003-05-30 | 2013-05-27 | Дженентек, Инк. | Лікування злоякісного новоутворення за допомогою бевацизумабу |
| AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| US20080085902A1 (en) * | 2003-09-23 | 2008-04-10 | Guido Bold | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent |
| WO2006001911A2 (en) | 2004-05-06 | 2006-01-05 | Genentech, Inc. | Crystal structure of the hepatocyte growth factor beta chain and methods of use |
| NZ579482A (en) | 2004-06-01 | 2011-02-25 | Genentech Inc | Antibody drug conjugates and methods |
| AU2005249566B2 (en) | 2004-06-04 | 2010-11-11 | Genentech, Inc. | Method for treating multiple sclerosis |
| GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| US8772269B2 (en) * | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| CN101146532B (zh) * | 2005-01-21 | 2012-05-09 | 阿斯泰克斯治疗有限公司 | 药物化合物 |
| KR20070114753A (ko) * | 2005-02-18 | 2007-12-04 | 아브락시스 바이오사이언스 인크. | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| CA2599301A1 (en) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | Novel use of sulfonamide compound in combination with angiogenesis inhibitor |
| EP3527202A1 (en) * | 2005-08-31 | 2019-08-21 | Abraxis BioScience, LLC | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| LT3311805T (lt) * | 2005-08-31 | 2020-04-27 | Abraxis Bioscience, Llc | Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus |
-
2006
- 2006-11-06 US US11/594,417 patent/US20070166388A1/en not_active Abandoned
-
2007
- 2007-11-06 EP EP16161396.3A patent/EP3108885A1/en not_active Withdrawn
- 2007-11-06 MX MX2009004803A patent/MX2009004803A/es active IP Right Grant
- 2007-11-06 KR KR1020157014446A patent/KR20150065957A/ko not_active Ceased
- 2007-11-06 PT PT121549950T patent/PT2481405E/pt unknown
- 2007-11-06 DK DK07839976.3T patent/DK2097078T3/da active
- 2007-11-06 SI SI200731795A patent/SI2481405T1/sl unknown
- 2007-11-06 EP EP12154995.0A patent/EP2481405B1/en active Active
- 2007-11-06 AU AU2007317859A patent/AU2007317859B2/en active Active
- 2007-11-06 CN CNA2007800490545A patent/CN101573108A/zh active Pending
- 2007-11-06 RU RU2009121568/15A patent/RU2009121568A/ru unknown
- 2007-11-06 NZ NZ576856A patent/NZ576856A/en not_active Application Discontinuation
- 2007-11-06 CA CA002668607A patent/CA2668607A1/en not_active Abandoned
- 2007-11-06 BR BRPI0718528-6A patent/BRPI0718528A2/pt not_active Application Discontinuation
- 2007-11-06 ES ES12154995.0T patent/ES2576289T3/es active Active
- 2007-11-06 PL PL12154995.0T patent/PL2481405T3/pl unknown
- 2007-11-06 HU HUE12154995A patent/HUE028472T2/en unknown
- 2007-11-06 JP JP2009536282A patent/JP5931323B2/ja active Active
- 2007-11-06 PT PT78399763T patent/PT2097078E/pt unknown
- 2007-11-06 PL PL07839976T patent/PL2097078T3/pl unknown
- 2007-11-06 DK DK12154995.0T patent/DK2481405T3/en active
- 2007-11-06 SI SI200731475T patent/SI2097078T1/sl unknown
- 2007-11-06 KR KR1020187002044A patent/KR20180012339A/ko not_active Withdrawn
- 2007-11-06 KR KR1020177002657A patent/KR101857142B1/ko active Active
- 2007-11-06 KR KR1020097011640A patent/KR20090087906A/ko not_active Ceased
- 2007-11-06 CN CN201510264733.0A patent/CN104940929A/zh active Pending
- 2007-11-06 ZA ZA200903132A patent/ZA200903132B/xx unknown
- 2007-11-06 EP EP07839976.3A patent/EP2097078B1/en active Active
- 2007-11-06 ES ES07839976.3T patent/ES2469716T3/es active Active
- 2007-11-06 WO PCT/US2007/023446 patent/WO2008057562A1/en not_active Ceased
-
2009
- 2009-05-05 IL IL198576A patent/IL198576A/en active IP Right Grant
- 2009-06-05 NO NO20092179A patent/NO343908B1/no unknown
-
2013
- 2013-11-05 RU RU2013149282A patent/RU2673805C2/ru active
- 2013-11-07 JP JP2013230872A patent/JP2014043454A/ja not_active Withdrawn
-
2014
- 2014-06-26 CY CY20141100462T patent/CY1115271T1/el unknown
-
2015
- 2015-10-23 JP JP2015208557A patent/JP2016014073A/ja active Pending
-
2016
- 2016-03-02 IL IL244390A patent/IL244390A/en active IP Right Grant
- 2016-06-17 CY CY20161100552T patent/CY1117725T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509331A5 (https=) | ||
| RU2009121568A (ru) | Комбинации и способы введения терапевтических агентов и комбинированная терапия | |
| Agnello et al. | Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors | |
| JP2010529025A5 (https=) | ||
| JP2013503174A5 (https=) | ||
| Guo et al. | Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery | |
| JP2016506908A5 (https=) | ||
| JP2012520323A5 (https=) | ||
| JP2013523656A5 (https=) | ||
| JP2013527233A5 (https=) | ||
| US12391944B2 (en) | Magnetic inorganic iron-based nanoparticles | |
| JP2016513075A5 (https=) | ||
| JP2016505018A5 (https=) | ||
| JP2014531456A5 (https=) | ||
| RU2012157805A (ru) | Способы лечения рака мочевого пузыря | |
| JP2016513657A5 (https=) | ||
| HRP20160609T1 (hr) | Postupci liječenja hepatocelularnog karcinoma | |
| JP2013520442A5 (https=) | ||
| JP2012158602A5 (https=) | ||
| EP2481402A3 (en) | Nanoparticle comprising rapamycin and albumin as anticancer agent | |
| JP2010523696A5 (https=) | ||
| JP2015517529A5 (https=) | ||
| WO2013173542A4 (en) | Methods for treating cancer with notch2/3 antibodies | |
| JP2017514800A5 (https=) | ||
| JP2021500349A5 (https=) |